Grundy SM, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139:e1046–e1081. doi: 10.1161/CIR.0000000000000624

• PubMed
Grundy SM, AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139:e1046–e1081. doi: 10.1161/CIR.0000000000000624)| false
• Search Google Scholar
• Export Citation

Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41(4 Suppl 3):I–IV, S1–91. PMID: 12671933

• PubMed
Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41(4 Suppl 3):I–IV, S1–91. PMID: 12671933)| false
• Search Google Scholar
• Export Citation

Campese VM and Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int 2007; 71:1215–1222. doi: 10.1038/sj.ki.5002174

• PubMed
Campese VM and Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int 2007; 71:1215–1222. doi: 10.1038/sj.ki.5002174)| false
• Search Google Scholar
• Export Citation

Dichtl W, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23:58–63. doi: 10.1161/01.atv.0000043456.48735.20

• PubMed
Dichtl W, HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23:58–63. doi: 10.1161/01.atv.0000043456.48735.20)| false
• Search Google Scholar
• Export Citation

Nikolic D, et al. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol 2013; 168:5437–5447. doi: 10.1016/j.ijcard.2013.08.060

• PubMed
Nikolic D, A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol 2013; 168:5437–5447. doi: 10.1016/j.ijcard.2013.08.060)| false
• Search Google Scholar
• Export Citation

Otto A, et al. Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: Implication of the NAD(P)H oxidase pathway. Br J Pharmacol 2006; 148:544–552. doi: 10.1038/sj.bjp.0706738

• PubMed
Otto A, Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: Implication of the NAD(P)H oxidase pathway. Br J Pharmacol 2006; 148:544–552. doi: 10.1038/sj.bjp.0706738)| false
• Search Google Scholar
• Export Citation

Vieira Jr JM, et al. Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol Dial Transplant 2005; 20:1582–1591. doi: 10.1093/ndt/gfh859

• PubMed
Vieira Jr JM, Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol Dial Transplant 2005; 20:1582–1591. doi: 10.1093/ndt/gfh859)| false
• Search Google Scholar
• Export Citation

Food U.S. and Drug Administration. Rosuvastatin calcium (marketed as Crestor) information. Content current as of July 10, 2015. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/rosuvastatin-calcium-marketed-crestor-information

• PubMed
Food U.S. and Drug Administration. Rosuvastatin calcium (marketed as Crestor) information. Content current as of July 10, 2015. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/rosuvastatin-calcium-marketed-crestor-information)| false
• Search Google Scholar
• Export Citation

Scott LJ, et al. Rosuvastatin: A review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs 2004; 4:117–138. doi: 10.2165/00129784-200404020-00005

• PubMed
Scott LJ, Rosuvastatin: A review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs 2004; 4:117–138. doi: 10.2165/00129784-200404020-00005)| false
• Search Google Scholar
• Export Citation

Shin J-I, et al. Association of rosuvastatin use with risk of hematuria and proteinuria. J Am Soc Nephrol [published online ahead of print July 19, 2022]. doi: 10.1681/ASN.2022020135; https://jasn.asnjournals.org/content/early/2022/07/19/ASN.2022020135

• PubMed
Shin J-I, Association of rosuvastatin use with risk of hematuria and proteinuria. J Am Soc Nephrol [published online ahead of print July 19, 2022]. doi: 10.1681/ASN.2022020135; https://jasn.asnjournals.org/content/early/2022/07/19/ASN.2022020135)| false
• Search Google Scholar
• Export Citation

Luvai A, et al. Rosuvastatin: A review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol 2012; 6:17–33. doi: 10.4137/CMC.S4324

• PubMed
Luvai A, Rosuvastatin: A review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol 2012; 6:17–33. doi: 10.4137/CMC.S4324)| false
• Search Google Scholar
• Export Citation

Agarwal R. Statin induced proteinuria: Renal injury or renoprotection? J Am Soc Nephrol 2004; 15:2502–2503. doi: 10.1097/01.ASN.0000143720.71748.79

• PubMed
Agarwal R. Statin induced proteinuria: Renal injury or renoprotection? J Am Soc Nephrol 2004; 15:2502–2503. doi: 10.1097/01.ASN.0000143720.71748.79)| false
• Search Google Scholar
• Export Citation

Verhulst A, et al. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004; 15:2249–2257. doi: 10.1097/01.ASN.0000136778.32499.05

• PubMed
Verhulst A, Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004; 15:2249–2257. doi: 10.1097/01.ASN.0000136778.32499.05)| false
• Search Google Scholar
• Export Citation

Bargossi AM, et al. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med 1994; 15(Suppl):s187–s193. doi: 10.1016/0098-2997(94)90028-0

• PubMed
Bargossi AM, Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med 1994; 15(Suppl):s187–s193. doi: 10.1016/0098-2997(94)90028-0)| false
• Search Google Scholar
• Export Citation

van Zyl-Smit R, et al. Renal tubular toxicity of HMG-CoA reductase inhibitors. Nephrol Dial Transplant 2004; 19:3176–3179. doi: 10.1093/ndt/gfh474

• PubMed
van Zyl-Smit R, Renal tubular toxicity of HMG-CoA reductase inhibitors. Nephrol Dial Transplant 2004; 19:3176–3179. doi: 10.1093/ndt/gfh474)| false
• Search Google Scholar
• Export Citation